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Abstract
Haemophilus influenzae is a leading cause of meningitis disease and mortality, particularly in young children. Since the 
introduction of a licensed conjugate vaccine (targeting the outer capsular polysaccharide) against the most prevalent serotype, 
Haemophilus influenzae serotype b, the epidemiology of the disease has changed and Haemophilus influenzae serotype a is 
on the rise, especially in Indigenous North American populations. Here we apply molecular modeling to explore the preferred 
conformations of the serotype a and b capsular polysaccharides as well as a modified hydrolysis resistant serotype b polysac-
charide. Although both serotype b and the modified serotype b have similar random coil behavior, our simulations reveal 
some differences in the polysaccharide conformations and surfaces which may impact antibody cross-reactivity between 
these two antigens. Importantly, we find significant conformational differences between the serotype a and b polysaccha-
rides, indicating a potential lack of cross-reactivity that is corroborated by immunological data showing little recognition or 
killing between heterologous serotypes. These findings support the current development of a serotype a conjugate vaccine.
Keywords Haemophilus influenzae type a · Capsular polysaccharide · Conformation · Cross protection · Molecular 
modeling · Immunogenicity
Introduction
Haemophilus influenzae is a Gram-negative coccobacillus 
that is a leading cause of meningitis, otitis media, bactere-
mia, and pneumonia, amongst others, particularly in children 
younger than five and immune-compromised individuals, 
with high levels of morbidity and disability [1–4]. There 
are six encapsulated serotypes, a – f, based on the capsular 
polysaccharide (CPS) structure as well as unencapsulated, 
non-typeable H. influenzae (NTHi) strains [1, 5, 6]. H. 
influenzae type b (Hib) was the leading cause of invasive 
H. influenzae disease prior to the introduction of conjugate 
vaccines in the 1980s and 1990s [2, 3, 7, 8]. The successful 
introduction of Hib vaccination in many regions has changed 
the epidemiology of H. influenzae disease and resulted in 
the near elimination of Hib disease. Most invasive disease is 
now caused by non-b serotypes and NTHi strains, with Hia 
appearing as a leading cause of disease in Indigenous chil-
dren in North America [1–3, 8–10]. The emergence of Hia 
disease despite widespread Hib vaccination suggests that 
Hib does not cross-protect against Hia and is the motivation 
for development of a Hia conjugate vaccine. This is aligned 
with the WHO priority in their “Defeating meningitis by 
2030: a global roadmap”, particularly as the distribution 
and burden of disease is underestimated in low- and middle-
income countries (LMICs) [4, 6, 9].
Licensed conjugate vaccines against Hib—based on the 
immunogenic CPS conjugated to different carrier proteins—
are available and implemented in national immunization 
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programs of all countries except for China and the Rus-
sian Federation [4, 11, 12]. For Hia, a promising candidate 
conjugate vaccine—which is expected to be cost effective 
in affected areas—has been developed and tested in pre-
clinical studies; it showed immunogenicity, functional 
antibody stimulation (by serum bactericidal assay), and 
protective titers equivalent to that of the PedVaxHIB® vac-
cine (OMPC carrier) [2, 8, 10, 13, 14]. A North Ameri-
can consortium including researchers at McGill University, 
Dalhousie University, National Research Council, Canadian 
Immunisation Research Network, Canadian Glycomics Net-
work and Inventprise LLC has identified funds to support 
GMP clinical lot production, GLP-toxicology studies and a 
Phase 1 clinical trial of the candidate Hia conjugate vaccine 
that is scheduled to take place in 2022 [A. Cox, personal 
communication].
The disaccharide repeating unit structures of the Hib and 
Hia CPS are similar. The Hib repeating unit (RU)—also 
commonly known as known as polyribosylribitolphosphate 
(PRP)—contains ribose, in the β-furanose form, (Ribf) as well 
as ribitol phosphate (Rib-ol) linked by a 1,5-phosphodiester 
bond (Fig. 1a), whereas Hia contains β-glucopyranose (Glc) 
and Rib-ol linked via a 4,5-phosphodiester bond (Fig. 1c) [15, 
16]. Ribitol phosphate is not present in the CPS of the other 
H. influenzae serotypes [5, 17].
Hib vaccines have poor stability due to the susceptibil-
ity of the PRP to hydrolytic cleavage of the phosphodiester 
bond through nucleophilic attack from O2 of Ribf – which 
Fig. 1  Primary line structures 
and repeating units of the CPS 
modeled in this work: (a) H. 
influenzae type b (Hib), (b) non-
biological stabilized Hib with a 
methyl group at O2 of Ribf, (c) 




is further catalyzed by the presence of divalent cations and 
some adjuvants [18–20]. This must be circumvented when 
designing the purification of the CPS, its conjugation and, 
particularly, its formulation in liquid combination vaccines 
[21]. One solution could be the use of a stabilized Hib anti-
gen. The first example of a conjugate vaccine with a fully 
synthetic carbohydrate moiety is the QuimiHib made in 
Cuba [4, 11, 12]; more recently a modular synthetic route 
was proposed which identified an octasaccharide lead vac-
cine candidate [22]. The same group showed that methyla-
tion at O2 of Ribf (see Fig. 1b, HibMe) provides a method 
for preventing hydrolytic cleavage, thus improving vaccine 
stability even in the presence of basic aqueous media or alu-
minum salts, as well as at elevated temperatures, while still 
inducing an immune response against Hib [19, 20].
As cross-protection between antigens is expected to 
require both chemical and conformational similarity [23], 
molecular modeling can provide insight into the potential 
for cross-protection between the H. influenzae CPSs and 
stabilized Hib. While the structures of H. influenzae type a 
and b polysaccharides have been fully characterized through 
wet-chemical assays and NMR [16, 24–27], conformational 
studies have been limited. Physicochemical studies of Hib 
CPS and a size-reduced activated intermediate showed that 
Hib behaves as highly flexible random coil [28]. Two dec-
ades ago, short molecular dynamics (MD) simulations of 
one RU of the Hib CPS showed a very flexible phospho-
diester linkage [27, 29]. To date, we are not aware of any 
conformational studies on CPS of Hia or methyl stabilized 
Hib (HibMe).
To provide insight into potential cross-reactivity between 
the antigens, in this work we ran microsecond MD simula-
tions of 6 RU of Hib as well as the vaccine candidates Hia 
and HibMe (Fig. 1) in order to compare the flexibility and 
dominant conformations of the polysaccharide chains. For 
experimental corroboration, we also investigated the cross-
reactivity between Hib and Hia by performing immunologi-
cal studies in rabbits.
Methods
Molecular simulations
We used our established systematic approach to the mode-
ling of polysaccharides, as follows [30, 31]. We ran Molecu-
lar Dynamics (MD) simulations in solution for CPS chains of 
3RU (data not shown) and 6 RU. Chain length is an impor-
tant consideration when modeling CPSs, as a short chain 
may have insufficient molecular flexibility, while long chains 
are more computationally expensive to model. Antibodies 
have been shown to only bind small fragments of the CPS 
between one and seven residues in length corresponding to 
1–4 RU in the case of H. influenzae [32]. Further, native H. 
influenzae CPS is very large and typically sized reduced for 
use in conjugate vaccines, with 5RU considered sufficient 
to induce immunity against Hib [11, 22, 33].
Following initial system equilibration, molecular dynam-
ics runs of 1.3 µs were performed and data analyses were 
performed on these production runs.
Molecular dynamics
Simulations were run using NAMD (version 2.13) [34] with 
CUDA extensions for graphics processor acceleration [35]. 
The CHARMM36 additive force field used to model the 
carbohydrates [36, 37] and TIP3P to model the water mol-
ecules [38]. To represent missing glycosidic linkages, we 
added patches to the CHARMM36 force field for carbohy-
drates, as well as the necessary bond, angle and dihedral 
parameters. These were copied from similar linkages in the 
existing force field. Meso-ribitol, which has a number of 
alditols, is available in the CHARMM carbohydrate force 
field. Phosphodiester linkage parameters were adapted from 
those we previously added to the force field [39]. The initial 
coordinate files (.pdb format) and associated molecular force 
field files (protein structure file format, .psf) for all systems 
modeled are provided as online resources 1–6.
Starting structures for each molecule (Fig. 1 and Fig. S1) 
were built with CarbBuilder [40] using the default glycosidic 
linkages designated by CarbBuilder: for the β-linkages φ, 
ψ = 40, 0 and for the phosphodiester linkages φ, ψ = -40, 0. 
These initial structures were then minimized with NAMD 
for 10 000 steps at 300 K.
Minimized structures were solvated using the Visual 
Molecular Dynamics (VMD) software [41] to add cubic 
water boxes of 60 Å per side for Hib/HibMe and 72 Å per 
side for Hia. Each system was ionized with sodium  (Na+) 
counter ions to neutralize the system (3 ions for the 3RU, 
6 for the 6 RU) at an ionic concentration of 0.027 mol/L 
and 0.046 mol/L for the 72 Å and 60 Å boxes respectively. 
Initial minimization and heating protocols comprised 5 K 
incremental temperature reassignments beginning at 10 K 
up to 300 K with 5 000 steps of NAMD minimization and 2 
000 steps of MD at each temperature reassignment.
Periodic boundary conditions equivalent to the cubic box 
size were employed for the solvated simulation with wrap-
ping on. Long range electrostatics were implemented with 
Particle Mesh Ewald summation (PME) on a 60 Å (Hib/
HibMe) or 72 Å (Hia) grid size [42]. Atoms were not held 
fixed, and the initial center of mass motion was off. The 
1–3 pairs were excluded from non-bonded interactions, 1–4 
interactions were not scaled, and the dielectric constant was 
set to 1. Smoothing functions were applied to both the elec-
trostatics and van der Waals forces with switching and cut-
off distances of 12 Å and 15 Å, respectively.
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A Leap-Frog Verlet integrator was used to integrate the 
equations of motion over a step size of 1 fs. A distance of 
18 Å was used as the cut-off for inclusion in the pair list 
for calculation of non-bonded forces. The short-range non-
bonded interactions were calculated every 1 fs, full electro-
statics calculations were performed every 2 fs, and atoms 
were reassigned every 10 fs [43].
Simulations were sampled under isothermal-isobaric 
(nPT) ensemble. Langevin dynamics were used to control 
the temperature with a damping coefficient of 5/ps. Nosé-
Hoover Langevin piston dynamics were used as a barostat to 
maintain a target pressure of 1 atm. Variable system volume 
was used with a piston period of 100 fs and decay of 50 fs. 
Post equilibration (200 ns), simulations underwent produc-
tion runs of 1300 ns as was required for the different models 
to converge.
Convergence
We addressed convergence using block standard averaging 
[44] applied to two metrics: end-to-end distance and radius 
of gyration (Supplementary Fig. S2). Block standard averag-
ing was implemented with in-house Python scripts, as previ-
ously described [30, 44].
For all simulations, the blocked standard error (BSE) 
reached plateaus for both metrics, indicating convergence. 
The simulation lengths were large multiples of the corre-
lation times for end-to-end distance (Hib, 11 ns; HibMe, 
11 ns; Hia, 24 ns) and radius of gyration (Hib, 11 ns; HibMe, 
11 ns; Hia, 25 ns). Further, the numbers of independent sam-
ples were > > 1 for both the end-to-end distance (Hib, 143; 
HibMe, 131; Hia, 64) and the radius of gyration (Hib, 131; 
HibMe, 142; Hia, 60). Our designated equilibration time of 
200 ns is therefore much greater than the correlation time.
Data analysis
Output trajectories were extracted every 25 ps and analyzed 
at 250 ps intervals. Inter-atomic distances and dihedral 
angles were measured using VMD, with data analyses per-
formed with in-house Python scripts and plots generated 
using Matplotlib [45].
The end-to-end distance, r, was measured from C1 of 
Rib-ol at the non-reducing end, to C1 of Ribf (for Hib) or 
Glc (for Hia) at the reducing end, thus excluding the highly 
flexible terminal residues.
The glycosidic linkages Ribf(11)Rib-ol and Glcp(14)
Rib-ol are described by two dihedral angles φ = H1-C1-O1-
Cx’ and ψ = C1-O1-Cx’-Hx’, which are equivalent to φH and 
ψH in IUPAC nomenclature [46, 47]. The phosphodiester 
linkages were defined as: φ =  Hx-Cx-Ox-P, ψ =  Cx-Ox-P-Oy, 
ω =  Ox-P-Oy-Cy and ε = P-Oy-Cy-Hy as we have previously 
done for this type of linkage [48]. All dihedral angles were 
measured as a combination of the dihedrals from the central 
RUs, three and four thus providing a sample of the most 
central angles.
The most common chain conformations for each simula-
tion were determined by clustering the simulations frames 
(post equilibration) into families and calculating the rela-
tive occupancies of each family. Clusters comprising less 
than 2% of the production run (post equilibration) were dis-
carded. Clustering was performed using the WMC PhysBio 
plug-in for VMD’s built-in cluster command [49]. Prior to 
clustering, the molecules were aligned on the ring and link-
age atoms of the central Rib-ol residue of RU 3 and Ribf 
residue of RU 4. Clustering was performed as an RMSD fit 
to the ring and linkage atoms of the central 4 RU of the 6 
RU chains (excluding the highly flexible terminal repeating 
units) with a cut-off of 5.5 Å.
Hydrophilic/hydrophobic regions of the molecular sur-
face were analyzed using VMD’s built in “measure sasa” 
command. The solvent accessible surface area (sasa) analy-
sis was performed by probing first hydrophilic regions (com-
prising hydroxyl groups, carbonyl groups, ring oxygens, 
phosphorous, and linkage oxygens) and then hydrophobic/
neutral regions (comprising methyl groups,  CH2 groups, ring 
carbons, and ring protons) of the molecule using a van der 
Waal’s radius of 1.4 Å—analogous to that of water. The 
ratio of hydrophilic to hydrophobic/neutral regions was then 
calculated to determine the percentage hydrophilic surface 
area available for potential antibody binding.
Molecular conformations were visualized using VMD, 
with the PaperChain visualization algorithm used to high-
light carbohydrate rings [50]. and the hydrophilic and hydro-
phobic surfaces were visualized with the Quicksurf visuali-
zation algorithm [51].
Immunological studies
CPS from Hia and Hib were isolated from cell supernatants 
following fermenter growth, as described previously for Hia, 
however, no RNase treatment was utilized for Hib CPS isola-
tion [8].  CRM197 carrier protein was prepared as described 
previously [8]. Conjugates of purified Hia and Hib CPS were 
prepared via direct reductive amination as described previ-
ously for the Hia conjugates [8].
Three New Zealand female white rabbits (Hia: RCAV1-
3), (Hib: RCBV1-3) were immunized sub-cutaneously with 
each conjugate at a 25 μg dose with the same prime and two 
boost strategy and adjuvanting with incomplete Freund’s 
adjuvant as described previously [8].
Final bleed day 70 (D70) rabbit sera from Hia and Hib 
conjugates were screened against BSA conjugates of Hia and 
Hib PS in ELISA as described previously [8]. Pre-immune 
sera were employed as the negative control.
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Final bleed (D70) rabbit sera from Hia and Hib conju-
gates were screened for functionality in a serum bacteri-
cidal assay (SBA) against Hia strain (NRCC # 6753) and 
Hib strain (NRCC # 4274) as described previously [8]. Pre-
immune sera were employed as the negative control.
Results
We begin with a comparison of the flexibilities of the Hib, 
HibMe, and Hia CPS chains, then the molecular confor-
mations, followed by the minimal binding epitopes and the 
characteristics of the molecular surface. We then discuss 
the results of our immunological studies in the light of the 
modeling results.
Chain flexibility
Time series graphs of the molecular end-to-end distance, 
r, over the course of the MD simulations provide a simple 
metric for comparison of the molecular flexibility and exten-
sion of the 6 RU CPS chains. The r time series plots (Fig. 2, 
left column) and corresponding histograms (Fig. 2, right 
column) reveal that all three molecules are very flexible, 
Fig. 2  Time series of the end-to-end distance, r, in the 6 RU CPS 
chains. Here r is defined as the distance (Å) from C1 of Rib-ol in RU 
1 to C1 of Ribf in RU 6 for Hib and HibMe (a), or the equivalent C1 
of Glc in RU 6 (for Hia). Time series (left column) and histograms 
(right column) are plotted for r in (b) Hib, (c) HibMe, and (d) Hia. 
Histograms are labelled with the standard deviation, σ
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with rapid transition between a wide range of r values. The 
similarity of the plots for Hib (Fig. 2b) and HibMe (Fig. 2c) 
indicate that the O-methyl substitution on Hib does not affect 
the flexibility of the chain substantially: Hib and HibMe 
have the same range of r (5–55 Å), although the r histograms 
reveal that Hib has a greater incidence of conformations with 
r < 10 Å. However, Hib and HibMe together are considerably 
more flexible than Hia (Fig. 2d). The range of r is considera-
bly broader for Hib and HibMe than for Hia (5–45 Å), which 
lacks the extreme extensions of the chain. Further, the more 
compact distribution of Hia (σ = 7 Å), with a clear peak at 
approximately 30 Å, indicates that it is more conformation-
ally defined than either Hib (σ = 10 Å) or HibMe (σ = 9 Å).
Molecular conformations
The flexibility of the CPS antigens is further demonstrated 
in a comparison of the dominant CPS chain conformations 
for Hib, HibMe, and Hia (Fig. 3). Hib has no dominant con-
formation, with the highest occupation for a conformational 
family at 7% of simulation time (Fig. 3a, Hib1). The wide 
range of collapsed (Fig. 3a: Hib1, Hib2, Hib8) and extended 
(Fig. 3a: Hib3-7 and Hib9-10) conformations with low occu-
pancies (< 7%) for Hib is consistent with the random coil 
classification of this antigen on the basis of sedimentation 
studies [28]. The conformations of HibMe (Fig. 3b) are very 
similar to Hib, although with more extended chain confor-
mations: O-methyl substitution of the Ribf residue removes 
the compact conformations of Hib. However, there remains 
a wide range of conformations of the chain, which also 
behaves as a random coil.
In contrast, the conformations of Hia are much more 
defined and regular (Fig. 3c), with the primary cluster com-
prising 36% of the simulation (Fig. 3c, Hia1). Zig-zag con-
formations of the chain predominate (Fig. 3c, Hia1, Hia5, 
Hia6), with bends at the Rib-ol of each RU. More compact 
conformations with accordion-style folding of the zig-zag do 
occur with relatively high frequency (Fig. 3c, Hia2, Hia4, 
Hia8, Hia9), but very extended conformations of the chain 
are absent. The glycosidic linkages (Supplementary informa-
tion, Figs. S3 and S4) in the Hia simulations are more con-
strained and have different orientations than in Hib. Over-
all, Hia therefore has markedly different conformations and 
dynamics to Hib.
Binding epitopes
As the CPS regions bound by antibodies comprise one to 
seven residues [32], it is useful to compare the 6 RU CPS 
chains on this length scale. Figure 4 shows the three main 
conformations of the central 4 RU segment (comprising 2 
RU) for the Hib, HibMe, and Hia CPS chains. Overall, the 
three primary conformations of the 2 RU segments are much 
more consistent with each other than the conformations of 
the 6 RU chains.
At this scale it is clear that the flexible phosphodiester 
linkage acts as a hinge between repeating units for all three 
CPS chains. However, the conformations of the 2 RU seg-
ment are quite different across the three antigens. The pri-
mary conformations of Hib are compact, with sharp bends 
exposing the phosphate group (Fig. 4a), whereas the pri-
mary conformations for HibMe are more extended, with the 
O-methyl group quite exposed on the chain (Fig. 4b). For 
Hib (Fig. 4a) the sharp bends enable conformational col-
lapse and stabilizing interactions between the Rib-ol and 
opposing sides of the chain (Fig. 4d) likely increase the pref-
erence for collapsed over extended conformations in this 
CPS. For HibMe the bulky methyl group at O2 of Ribf pre-
vents collapse and more extended conformations therefore 
predominate.
Fig. 3  Conformational families for the middle 4 RU of the 6 RU CPS 
chains: (a) Hib, (b) HibMe and (c) Hia. Families are scaled to illus-
trate differences in their relative percentage occupancies. Residues 
are colored: Ribf, pink; Rib-ol, gray; Glc, blue. The phosphate groups 
are highlighted in purple and the methyls in red
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The more moderate bends in the Hia conformations 
(Fig. 4c) are due to the constrained 4,5 linked Rib-ol. Here 
the phosphate hinge exposes both the phosphate groups as 
well as the bulky C1-C3 portion of the Rib-ol for possible 
antibody binding (Fig. 4f).
Comparison of the solvent exposed hydrophilic and 
hydrophobic regions of the molecular surfaces further high-
lights significant differences between the CPS antigens that 
may affect antibody binding. Time series and histograms of 
the solvent exposed hydrophilic surface area for step in the 
simulation are plotted in Fig. 5. As expected, the surface 
of the Hib CPS (Fig. 5a) is largely hydrophilic (average of 
72%)—due primarily to the bulky charged phosphate groups. 
However, the addition of the hydrophobic methyl group in 
HibMe greatly reduces the hydrophilicity of the exposed 
molecular surface to an average of 57% (Fig. 5b). This can 
be rationalized by considering that the methyl group in 
HibMe is relatively bulkier (4 atoms) compared to the OH 
in Hib (2 atoms), thus the methyl substituent would con-
tribute more to the hydrophobicity of the molecular surface 
in HibMe than the OH contributes to hydrophilicity of the 
surface in Hib. In addition to the conformational differences 
in the chain, this difference in the properties of the surface 
is another factor to consider that may affect cross-reactivity 
between the two antigens.
Interestingly, the analysis shows that Hia (Fig. 5c) has 
the same relative hydrophilicity as Hib, an average of 
72% (with a narrower distribution), despite the signifi-
cant structural and conformational differences between 
these antigens. This is consistent with a comparison of the 
hydrophilic surfaces of the Ribf (Fig. S5a, 69%) and Glc 
(Fig. S5b, 69%) residues—which, given the common Rib-ol 
residue (Fig. S5c) contributes to the overall hydrophilicity 
of the surface.
Immunological studies
To investigate cross-reactivity between Hib and Hia, D70 
rabbit sera derived from immunizations with three doses 
of the Hia and Hib conjugates were screened in ELISA 
for recognition of the homologous and heterologous CPS 
(Fig. 6). Only the homologous CPS was recognized in each 
case, confirming a lack of cross-reactivity between the Hia 
and Hib CPS.
Fig. 4  Four residue sections of 
the CPS chains comprising RU 
3 and RU 4 for the three pri-
mary conformational clusters: 
(a) Hib, (b) HibMe and (c) Hia. 
The full primary clusters for 
Hib, HibMe, and Hia are shown 
in the last column. Residues 
are colored: Ribf, pink; Rib-ol, 
gray; Glc, blue. The phosphate 
groups are highlighted in purple 
and the methyls in red
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The same D70 sera were utilized in an SBA assay to 
assess for functionality of the sera that supports complement- 
mediated killing. As can be seen in Fig.  7, the Hia 
conjugate derived sera could only facilitate the killing of 
the Hia strain and not killing of the Hib strain. The same 
reciprocal results were obtained when the Hib conjugate 
derived sera were examined, confirming the inability of 
sera specific to one serotype to recognize nor facilitate 
the killing of the heterologous serotype strains.
Fig. 5  Time series plots and histograms of the percentage of the sol-
vent accessible surface area that is hydrophilic in the 6 RU simula-
tions of (a) Hib, (b) HibMe, and (c) Hia. Examples of the molecular 
surfaces for each CPS with hydrophilic (blue) and hydrophobic (pink) 
patches indicated are shown in the right column; the key and classifi-




We find that Hib and the modified HibMe CPS antigens 
both behave as unstructured random coils in solution. 
However, we show that there are also some differences 
between the Hib and HibMe saccharides that may affect 
antibody binding: Hib has a range of collapsed, globular 
conformations that do not occur in HibMe, the local con-
formation of the chain in Hib has more extreme bends than 
HibMe, and the molecular surface of Hib is much more 
hydrophilic than HibMe. However, despite the differences 
in conformation and molecular surface, a modified HibMe 
conjugate vaccine raised antibodies that recognized the 
natural Hib antigen [19]. This suggests that the presence 
of immuno-dominant charged phosphate [52] is the focus 
of antibody recognition and binding.
In contrast to Hib, the flexible Hia CPS forms relatively 
defined zig-zag conformations. We find significant differ-
ences between the Hia and Hib CPS antigens in flexibility, 
conformation, and minimal binding epitope, which does not 
support the existence of cross-reactivity between them. The 
immunological data confirms this: sera derived from Hia 
CPS conjugates cannot recognize nor kill Hib strains and 
sera derived from Hib CPS conjugates cannot recognize nor 
kill Hia strains. This is also consistent with clinical data 
showing an increase in invasive disease caused by serotype a 
in infants and children, even after receiving a full childhood 
serotype b conjugate vaccine regimen [53, 54]. Based on 
Fig. 6  ELISA screening of rabbit sera from Hia or Hib conjugate 
immunized rabbits (n = 3) for recognition of: (a) Hia-BSA conjugate 
or (b) Hib-BSA conjugate. Homologous serotype recognition is seen, 
but no cross-recognition of the heterologous serotype. In all cases the 
pre-immunization sera were used as the control
Fig. 7  Serum bactericidal assay (SBA) titration curves of rabbit sera 
from Hia or Hib conjugate immunized rabbits (n = 3) against: (a) Hia 
bacterial strain # 6753 or (b) Hib bacterial strain # 4274. We see kill-
ing of the homologous serotype, but a lack of cross-killing of the het-




the limited immunogenicity studies detailed herein, we also 
note that Hia appears to elicit a stronger immune response 
than the highly flexible Hib; it is interesting to postulate that 
the more conformationally defined Hia CPS is a stronger 
antigen than Hib.
Future work is focused on the development of a Hia gly-
coconjugate vaccine to protect all infants and children from 
this disease; funding has been secured for Phase 1 clini-
cal trial of a prospective Hia vaccine by a North American 
consortium.
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